LGI1 antibody encephalitis and intrathecal B-cell activation


  • The results from this study suggest that central nervous system (CNS) B cells could be a treatment target in those with leucine-rich, glioma-inactivated 1 (LGI1) antibody encephalitis.

Why this matters

  • Little is known about the cerebrospinal fluid (CSF) B-cell response against LGI1 in the periphery or CSF, and given that LGI1 antibody encephalitis often results in neurological and cognitive impairment, this information is greatly sought.

  • With this information, further therapeutic targets can be identified and tested, thus giving rise to new, more specific, treatments.